Reishi Mushroom & Liver Safety: What Evidence Shows (2026)

Key Takeaways

The NIH LiverTox database classifies reishi-associated hepatotoxicity as extremely rare given the widespread global use of Ganoderma lucidum. A 2023 case report and literature review by Dr. Richard Guedikian cataloged the documented cases and found the majority involved powdered, unextracted whole-mushroom products rather than standardized hot-water or dual extracts (Guedikian et al., 2023, Cureus). Standardized reishi extracts with verified beta-glucan content and third-party heavy-metal testing present a substantially lower risk profile than unprocessed reishi powder.

📑 In This Article

• The question everyone asks
• What NIH LiverTox says
• Case reports: what happened
• The hepatoprotective paradox
• Who is at risk
• Powder vs. extract: why form matters
• How to use reishi safely
• Liver tests: what to monitor

If you've been Googling "reishi mushroom liver toxicity" at midnight after reading a scary headline, take a breath. You're in the right place. We sell reishi-containing products, and we're still writing this article, because we think transparency about safety is what an honest supplement brand does. We'd rather you have the complete picture than a marketing-friendly half-truth.

This article covers what the NIH and clinical institutions say, what the actual case reports show (including the details most summaries leave out), the paradox of reishi being both hepatoprotective and hepatotoxic, who faces elevated risk, and exactly what to do to minimize it. If you're also interested in the benefits side of reishi, we have a separate evidence-based guide for that.

Is Reishi Mushroom Bad for Your Liver? The honest answer

For most healthy adults, reishi at normal doses of 1 to 3 g/day appears safe for the liver, and controlled trials show no enzyme changes. Rare liver-injury reports involved high doses, raw powder rather than extract, or alcohol use. Choose standardized extract, keep doses moderate, and avoid pairing it with heavy drinking.

No, reishi is not categorically bad for your liver. But it's not universally safe for every person in every form at every dose, either. Evidence paints a more specific picture: reishi extracts at standard doses in healthy people appear safe in controlled trials; reishi powder (unextracted) used for more than one month, or combined with alcohol or certain medications, carries a small but real risk of liver injury.

This confusion comes from two sets of evidence that seem to contradict each other. Laboratory studies consistently show that reishi compounds, particularly triterpenoids and polysaccharides — have hepatoprotective properties. They reduce oxidative stress, modulate inflammatory pathways, and protect liver cells from damage in animal models (Ahmad et al., 2023, PubMed). At the same time, a handful of clinical case reports document liver injury in people taking reishi products. Both findings are real. Context explains the contradiction: product form, dose, duration, and individual risk factors.

Here's one thing competitors won't say: this is the same pattern seen with many traditional herbal medicines. Green tea extract, turmeric/curcumin, and ashwagandha all have hepatoprotective preclinical data AND rare liver injury case reports. Supplement-liver relationships are almost never black-and-white. If you're also taking berberine or ashwagandha, the same careful approach to liver safety applies.

What NIH LiverTox says, the most authoritative source

While adaptogenic mushrooms like lion’s mane and reishi have some clinical research behind them, the doses found in blended mushroom coffee products are often well below what those studies used, so expectations should be calibrated accordingly.

According to Vikineswary Sabaratnam, PhD of the Mushroom Research Centre at the University of Malaya, the compounds that drive these effects differ widely from one species to another, and reishi and lion's mane rank among the few with the strongest clinical support.

Paul Stamets, mycologist and author of Mycelium Running, has pointed out that the beta-glucans and other polysaccharides in functional mushrooms act on the immune system through separate pathways, and that different species carry meaningfully different bioactive profiles.

What is mushroom coffee?

Mushroom coffee provides lower caffeine (50 to 80 mg) than regular coffee plus adaptogenic mushroom compounds. The caffeine benefit is immediate; the mushroom benefits require weeks of consistent use. Whether it is "good for you" depends on your goals and expectations. See mushroom coffee benefits.

Does mushroom coffee have caffeine?

Yes, most mushroom coffee contains 50 to 80 mg of caffeine per serving, roughly half of a standard drip coffee. The caffeine comes from the coffee base, not the mushrooms. See how mushroom coffee works.

Is mushroom coffee good for you?

For most healthy adults, mushroom coffee is a reasonable lower-caffeine alternative to regular coffee, combining functional mushrooms like Reishi, Lion's Mane, and Chaga with a coffee base. Powdered Reishi is generally preferred over raw extracts of uncertain origin, since a small number of liver-related case reports involved unverified Reishi products rather than standardized supplements.

Is mushroom coffee good for your liver?

Reishi and other functional mushrooms are studied for antioxidant activity, and standardized products have a good safety record. The rare liver concerns reported in the literature involved powdered or unverified Reishi of unknown source, not third-party-tested supplements. Anyone with a liver condition should consult a clinician before use.

How Common Are Reishi Liver Toxicity Cases?

Extremely rare. As of early 2026, the NIH LiverTox database — the most authoritative source on supplement-induced liver injury — documents fewer than 10 published case reports worldwide linking reishi mushroom products to hepatotoxicity. Given that millions of people consume reishi supplements annually, the incidence rate is vanishingly low compared to common over-the-counter medications like acetaminophen (which causes approximately 500 deaths per year from liver failure in the United States alone).

However, "rare" does not mean "zero risk," and the case reports that do exist share several patterns worth examining. Most documented cases involved high-dose reishi powder (not standardized extract) consumed daily for extended periods (2–6 months). Several cases involved concurrent use of other potentially hepatotoxic substances — alcohol, prescription medications metabolized by CYP450 enzymes, or other herbal supplements. And in most cases, liver function normalized within 2–8 weeks of discontinuing reishi, suggesting the injury was idiosyncratic and reversible rather than dose-dependent and progressive.

What Dose of Reishi Is Considered Safe for the Liver?

Clinical trials have used doses ranging from 1.5 g to 5.4 g of reishi extract daily for periods up to 12 weeks without documenting liver enzyme elevation above normal limits. The Cochrane Database systematic review on Ganoderma lucidum for cancer treatment assessed multiple trials using doses of 600–3,600 mg of reishi extract daily and found no consistent hepatotoxic signal.

The case reports of liver injury tend to involve either very high doses (above 5 g daily of crude powder, which delivers a less controlled compound profile than standardized extracts), prolonged unsupervised use (months without liver function monitoring), or products with unclear quality control (potential contamination with heavy metals, mycotoxins, or adulterants). This suggests that the problem may not be reishi per se, but rather the dose, duration, and product quality — a distinction that gets lost in alarmist coverage.

A conservative, evidence-based approach: use standardized reishi extract (not raw powder) at doses of 500–1,500 mg daily. If you plan to take reishi for longer than 3 months continuously, request a basic liver panel (AST, ALT, ALP, bilirubin) from your doctor at the 3-month mark. This costs less than one month of supplements and provides objective reassurance. If liver enzymes are normal, continued use at the same dose is supported by the available evidence.

Who Is Most at Risk for Reishi-Related Liver Problems?

Three groups warrant extra caution: people with pre-existing liver disease, people taking hepatotoxic medications, and people consuming alcohol regularly in combination with reishi.

Pre-existing liver conditions. If you have hepatitis B or C, non-alcoholic fatty liver disease (NAFLD), cirrhosis, or any condition where liver function is already compromised, adding any supplement — including reishi — without hepatologist supervision is inadvisable. Compromised livers have reduced capacity to metabolize bioactive compounds, increasing the risk of accumulation and injury even at doses that would be safe for healthy individuals.

CYP450 drug interactions. Reishi contains triterpenoids (ganoderic acids) that may inhibit certain cytochrome P450 enzymes — the liver enzyme family responsible for metabolizing most pharmaceutical drugs. If you take statins (atorvastatin, simvastatin), immunosuppressants (cyclosporine, tacrolimus), blood thinners (warfarin), or certain antidepressants (SSRIs metabolized by CYP2D6), reishi could theoretically alter drug metabolism. This is a class effect shared by many herbal products (grapefruit, St. John's wort, turmeric), not unique to reishi — but it requires awareness and prescriber notification.

Regular alcohol consumption. Alcohol is directly hepatotoxic. Adding any liver-metabolized supplement on top of regular alcohol intake creates additive burden on hepatocytes. Two of the published reishi hepatotoxicity case reports noted moderate alcohol consumption as a co-factor. If you drink more than 7 drinks per week (women) or 14 drinks per week (men), discuss any herbal supplement with your physician before starting.

Does Reishi Extract vs. Reishi Powder Matter for Liver Safety?

Likely yes, though this has not been formally studied in a head-to-head liver safety trial. Standardized reishi extract and raw reishi powder are not the same product — they deliver different compound profiles at different concentrations.

Standardized extracts (typically dual-extracted with hot water and alcohol) concentrate specific bioactive fractions — polysaccharides (beta-glucans) and triterpenoids (ganoderic acids) — at known, reproducible concentrations. The extraction process also removes many non-bioactive plant materials, potential contaminants, and compounds that may contribute to adverse effects at high doses. When a supplement label says "500 mg reishi extract (30% polysaccharides)," you know approximately what you are getting.

Raw reishi powder is simply dried and ground mushroom material — fruiting body, sometimes including spores and stem. It contains the full spectrum of mushroom compounds (potentially including uncharacterized metabolites), along with chitin (a structural fiber that can cause GI distress in sensitive individuals), environmental contaminants absorbed during growth, and variable compound concentrations depending on growing conditions, harvest timing, and drying method. No two batches of raw reishi powder have identical chemistry.

Most published liver toxicity cases used high-dose raw powder rather than standardized extract. While this observation is associative (not causal), it aligns with basic pharmacological logic: controlled extracts at known doses are inherently safer than crude preparations at variable doses. If liver safety is a concern for you, standardized extract from a quality-tested brand is the lower-risk choice.

Can Reishi Actually Protect the Liver?

Yes, reishi has significant hepatoprotective evidence in both animal models and preliminary human research, which is the irony most "reishi liver damage" articles miss. The same mushroom accused of causing liver damage may, at appropriate doses, actually protect against it.

Ganoderic acids — the triterpenoid compounds in reishi — have demonstrated antioxidant, anti-inflammatory, and anti-fibrotic effects in liver tissue across multiple animal studies. A 2013 study in Food and Chemical Toxicology found that reishi polysaccharides protected rat hepatocytes against acetaminophen-induced liver damage by reducing oxidative stress markers (MDA, SOD, GSH-Px). A 2017 study in International Journal of Medicinal Mushrooms showed that ganoderic acid A reduced liver fibrosis in a carbon tetrachloride rat model — a standard model for studying liver protection compounds.

In traditional Chinese medicine, reishi (lingzhi) has been used for liver support for over 2,000 years — one of its primary traditional indications. Modern pharmacological research has validated several mechanisms: upregulation of Nrf2 (the master antioxidant transcription factor), inhibition of NF-κB (the master inflammatory transcription factor), and activation of hepatocyte regeneration pathways.

The resolution of the apparent contradiction — protective vs. toxic — likely lies in dose, duration, product quality, and individual susceptibility. Moderate doses of quality extract appear protective. High doses of crude powder in susceptible individuals (pre-existing liver disease, concurrent hepatotoxic substances) may overwhelm hepatic capacity. This is not unique to reishi; it is a basic dose-response principle that applies to everything from water to vitamin A.

What Liver Tests Should You Get Before and During Reishi Use?

A comprehensive metabolic panel (CMP) or hepatic function panel is the standard baseline assessment. Specifically, you want four values before starting reishi and at follow-up intervals.

AST (aspartate aminotransferase) and ALT (alanine aminotransferase) are the primary markers of hepatocyte injury. ALT is more liver-specific than AST (which can also be elevated from muscle damage). Normal ranges are typically 7–56 IU/L for ALT and 10–40 IU/L for AST, though reference ranges vary by lab and sex. Any elevation above 2× the upper limit of normal while taking reishi warrants immediate discontinuation and medical evaluation.

ALP (alkaline phosphatase) indicates biliary obstruction or cholestatic liver injury — a different pattern from hepatocellular injury (elevated AST/ALT). If ALP rises without AST/ALT elevation, the problem may be biliary rather than hepatocellular, which has different clinical implications and causes.

Bilirubin reflects the liver's conjugation and excretion capacity. Elevated bilirubin (jaundice — yellowing of skin or eyes) is a late-stage sign of significant liver dysfunction and requires immediate medical attention regardless of supplement use.

Recommended monitoring schedule for reishi supplementation: baseline panel before starting, follow-up at 3 months, then every 6 months if continuing indefinitely. This costs $20–50 per panel (often covered by annual physical bloodwork) and provides definitive evidence of liver safety for your specific situation. This level of monitoring is more conservative than necessary for most healthy adults, but it provides peace of mind and catches any idiosyncratic reaction early — when it is fully reversible by simply stopping the supplement.

What Are the Symptoms of Reishi-Induced Liver Injury?

The earliest warning signs are typically nonspecific and easy to dismiss: fatigue, loss of appetite, mild nausea, and upper-right abdominal discomfort. These symptoms overlap with dozens of benign conditions, which is why routine liver panels are the only reliable early detection method.

As liver injury progresses (if the supplement is not discontinued), more specific symptoms develop. Dark urine (cola-colored or brown) is often the first noticeable change, caused by conjugated bilirubin spilling into urine as the liver loses its ability to excrete it normally. Pale or clay-colored stools follow, reflecting reduced bile flow into the intestines. Jaundice (yellowing of the skin and the whites of the eyes) is a later sign that indicates significant hepatocellular dysfunction and requires immediate medical evaluation.

In the published reishi case reports, the typical timeline from first supplement dose to symptom onset ranged from 4 to 12 weeks. No case reported acute symptoms within the first few days of use, which distinguishes reishi-associated liver injury from allergic or immediate toxic reactions. This delayed onset pattern is characteristic of idiosyncratic drug-induced liver injury (DILI), where the mechanism involves gradual metabolic accumulation or immune-mediated sensitization rather than direct toxicity.

The critical takeaway: if you develop unexplained fatigue, digestive changes, or abdominal discomfort while taking reishi (or any herbal supplement), get a liver panel before assuming the cause is stress or diet. The test takes minutes and costs under $50. Early detection of elevated enzymes allows simple intervention (stop the supplement) before any structural liver damage occurs.

Is It Safe to Take Reishi Every Day Long-Term?

For most healthy adults taking standardized extract at recommended doses (500 to 1,500 mg daily), daily use appears safe based on the available evidence. Clinical trials lasting up to 12 weeks have not shown cumulative liver toxicity at these doses, and traditional use in East Asian medicine involves daily consumption over months to years.

That said, no randomized controlled trial has tracked daily reishi supplementation beyond 16 weeks with serial liver function monitoring. The longest safety data comes from observational studies and traditional use reports, which are inherently less rigorous than controlled trials. This does not mean long-term use is dangerous; it means the safety evidence beyond 4 months is based on clinical experience and pharmacological reasoning rather than gold-standard trial data.

If you plan to take reishi daily for longer than 3 months, a simple risk-mitigation protocol is to get baseline liver enzymes before starting and a follow-up panel at 3 months. If values remain normal, continue with annual monitoring (which most people get through routine physicals anyway). This approach gives you the benefits of consistent use while maintaining objective safety monitoring that catches any rare idiosyncratic reaction at a fully reversible stage.

Can Reishi Cause Kidney Damage or Other Organ Problems?

There is no published evidence linking reishi mushroom to kidney damage (nephrotoxicity) at supplemental doses. The kidney concern appears to be an extrapolation from the liver toxicity discussion, but the two organs have different metabolic pathways, and hepatotoxicity from one compound does not predict nephrotoxicity.

Reishi polysaccharides have actually shown nephroprotective effects in animal models of diabetic nephropathy, reducing proteinuria and improving creatinine clearance in rats with induced kidney disease. A 2018 study in the Journal of Ethnopharmacology found that Ganoderma lucidum polysaccharides attenuated renal fibrosis through suppression of TGF-beta1 signaling. These are animal studies, so direct human translation requires caution, but they point in the opposite direction from kidney damage.

Beyond liver and kidney, the most commonly reported side effects of reishi at standard doses are gastrointestinal: mild bloating, loose stools, or stomach discomfort, particularly when first starting supplementation or using high-dose raw powder. These GI effects are usually self-limiting (resolving within the first week of use) and can be minimized by taking reishi with food rather than on an empty stomach. In rare cases, reishi may cause dizziness, dry mouth, or skin irritation (primarily with topical reishi preparations, not oral supplements). Allergic reactions to reishi are possible but exceedingly rare and would typically present within hours of first exposure as hives, throat tightness, or respiratory difficulty.

Should You Stop Taking Reishi if Liver Enzymes Are Slightly Elevated?

Whether to stop reishi for slightly elevated liver enzymes depends on how elevated they are. A minor bump in ALT or AST (below 1.5 times the upper limit of normal) may not be caused by reishi at all. Many factors transiently elevate liver enzymes: intense exercise within 48 hours before the blood draw, alcohol consumption in the preceding days, certain foods, medications (statins, NSAIDs, acetaminophen), and even normal biological variation. A single mildly elevated result should be repeated in 2 to 4 weeks before attributing it to any supplement.

If repeat testing confirms persistent elevation above 1.5 times the upper limit of normal (for context, that means ALT above roughly 84 IU/L in most labs), discontinue reishi and recheck in 4 weeks. If enzymes normalize after stopping, you have a probable association. If they remain elevated, reishi was likely not the cause, and further medical workup is warranted regardless.

Elevations above 3 times the upper limit of normal (ALT above ~168 IU/L) at any single measurement warrant immediate discontinuation of all herbal supplements and urgent medical evaluation. At this level, the clinical concern shifts from monitoring to active diagnosis and potential intervention. This threshold applies to any supplement, not just reishi, and reflects standard clinical practice guidelines for drug-induced liver injury assessment.

For perspective on how to interpret these numbers: liver enzymes fluctuate naturally. AST and ALT can increase 30 to 50 percent from a single hard workout, a night of moderate drinking, or even acute sleep deprivation. The goal of monitoring is not to chase every minor fluctuation but to detect a sustained, progressive increase that indicates ongoing hepatocellular stress. A single data point in isolation is clinical noise; a trend across two or three measurements is actionable information.

Does Reishi Quality and Brand Matter for Safety?

Substantially. The gap between a rigorously tested reishi extract and a cheap, unverified reishi powder is not a minor quality difference but a fundamentally different risk profile. Product quality is arguably the single most important variable in reishi safety, more important than dose or duration.

Third-party tested products from brands that publish Certificates of Analysis (COAs) verify three critical safety parameters. First, they confirm identity: the product actually contains Ganoderma lucidum and not a cheaper substitute mushroom or filler material. Adulteration is a documented problem in the mushroom supplement market, and consuming the wrong species introduces entirely different (and unstudied) risks. Second, they verify the absence of contaminants: heavy metals (lead, arsenic, cadmium, mercury), pesticide residues, and mycotoxins (aflatoxins, ochratoxin A) that can be independently hepatotoxic. Several of the published reishi liver injury case reports could not rule out contamination as a contributing factor because the products involved lacked independent testing. Third, they confirm potency: standardized levels of polysaccharides and triterpenoids ensure you are getting a consistent dose rather than a variable amount that changes with every batch.

When evaluating reishi products, look for specific markers: beta-glucan content above 20 percent (indicating real mushroom extract rather than mycelium-on-grain filler), heavy metal testing to USP limits, and identification of the extraction method (dual extraction with hot water and alcohol captures both water-soluble polysaccharides and alcohol-soluble triterpenoids). Products that list only "reishi mushroom powder" without specifying extract ratios, beta-glucan content, or third-party testing should be avoided, not because reishi itself is dangerous, but because unverified products introduce controllable risks that have nothing to do with the mushroom's inherent pharmacology.

Is Reishi Safer Than Other Herbal Supplements for the Liver?

Reishi's liver safety profile is comparable to or better than most commonly used herbal supplements when standardized extract is used at recommended doses. Several widely consumed herbal products carry substantially higher hepatotoxicity risk based on published case volume and mechanistic evidence.

Green tea extract (EGCG) has generated far more hepatotoxicity case reports than reishi, with the NIH LiverTox database documenting over 50 cases of green tea extract-related liver injury (compared to fewer than 10 for reishi). Kava has been associated with severe hepatotoxicity leading to liver transplantation in multiple cases, resulting in regulatory bans in several European countries. Comfrey contains pyrrolizidine alkaloids that are directly hepatotoxic through a well-characterized mechanism (hepatic sinusoidal obstruction syndrome). Black cohosh, a popular menopause supplement, has generated enough hepatotoxicity signals that product labels in several countries now require liver warning statements.

This comparison is not meant to dismiss reishi liver concerns, but to contextualize them. Every bioactive substance carries some hepatic risk because the liver metabolizes everything you ingest. The question is always relative: compared to what? Compared to acetaminophen (the most common cause of acute liver failure in the United States), reishi is far safer. Compared to taking nothing, any supplement adds a small incremental risk. The risk-benefit calculation depends on your individual health goals, your baseline liver function, and whether you implement basic monitoring.

The practical bottom line for reishi and liver safety: choose a third-party tested, standardized extract from a reputable brand. Start at the low end of the dose range (500 mg daily). Get a baseline liver panel if you have any risk factors. Recheck at 3 months. If your enzymes are normal and you feel good, you have objective evidence that reishi is safe for your specific biochemistry. If you notice unexplained fatigue, GI changes, or dark urine at any point, stop the supplement and get tested promptly. This is the same monitoring protocol that responsible physicians recommend for any long-term medication or supplement, and it transforms a vague anxiety about liver toxicity into a concrete, manageable safety plan.

Related Reading

• Adaptogenic mushrooms: which species actually have human evidence
• How to choose a high-quality mushroom supplement

Our Batch-Level Purity Testing

Manufactured in a NSF International GMP-certified facility (NSF/ANSI 455-2 (2024), certification valid through January 20, 2027). Every batch of 10-Mushroom Complex Gummies undergoes independent third-party testing at a Eurofins (accredited); USP/AOAC methods for heavy metals and microbial contamination. Lot MCX250221 (COA issued 02/03/2026) passed every safety threshold.

Analytical methods: heavy metals via AOAC 2011.19, 993.14, 2015.01 (modified); microbiology per USP <2021>, USP <2022>; potency by NIR identity. The data below reflects batch-specific results — not general ingredient claims — verified under current Good Manufacturing Practices (21 CFR Part 111).

Testing performed by Eurofins (accredited); USP/AOAC methods. Serving size: 2 Gummies. Manufacturing date: N/A (exp 02/2029). Full batch results: yourhealthier.com/pages/lab-results. Original certificates of analysis available upon request.

Authoritative Resources

For independent, government-reviewed information on this ingredient, consult these primary sources:

• NIH LiverTox — Reishi (Lingzhi) Safety Profile

Testing & Transparency Methodology

Every YourHealthier product referenced here is manufactured in an FDA-registered facility and undergoes independent third-party testing at accredited laboratories (ISO/IEC 17025, A2LA, or Eurofins, depending on the product). Each batch is screened for heavy metals (lead, cadmium, mercury, arsenic) and microbial contamination (total plate count, yeast, mold, E. coli, Salmonella) using validated USP, AOAC, and ICP-MS methods. Batch-specific certificates of analysis are published at yourhealthier.com/pages/lab-results and updated with each new manufacturing run. All testing complies with current Good Manufacturing Practices (21 CFR Part 111). This article is written for general educational purposes and is not medical advice; it has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

References

1. NIH LiverTox (2024). "Lingzhi, Reishi." National Institute of Diabetes and Digestive and Kidney Diseases. Last updated October 5, 2024. NIH
2. Wicks SM, et al. (2007). "Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial." American Journal of Chinese Medicine, 35(3), 407–414. PubMed
3. Yuen MF, et al. (2004). "Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi)." Journal of Hepatology, 41(4), 686–687. PubMed
4. Guedikian R, et al. (2023). "Ganoderma lingzhi (Reishi Mushroom)-Induced Acute Liver Injury in the Setting of Alcohol Use: A Case Report and Review of the Literature." Cureus, 15(9), e45953. PubMed
5. ACG (2025). "S5705 Acute Liver Injury Associated With Reishi Mushroom Supplementation in a Patient on Chronic Acetaminophen Therapy." American Journal of Gastroenterology, 120(10S2), S3. ACG
6. Ahmad MF, et al. (2023). "Ganoderma lucidum: Novel Insight into Hepatoprotective Potential with Mechanisms of Action." Nutrients, 15(8), 1874. PubMed
7. Melek Arsoy HE, Özdemir Ö. (2026). "Acute neurotoxicity in a child following multi-component medicinal fungi supplementation: a case report." BMC Complement Med Ther. PubMed
8. Cor Andrejc D, et al. (2022). "Antioxidant, antibacterial, antitumor, antifungal, antiviral, anti-inflammatory, and nevro-protective activity of Ganoderma lucidum: An overview." Frontiers in Pharmacology, 13, 934982. PubMed
9. Memorial Sloan Kettering Cancer Center (2024). "Reishi Mushroom." Integrative Medicine monograph. MSKCC
10. Wachtel-Galor S, et al. (2004). "Ganoderma lucidum ('Lingzhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study." British Journal of Nutrition, 91(2), 263–269. PubMed
11. Wanmuang H, et al. (2007). "Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder." Journal of the Medical Association of Thailand, 90(1), 179–181. PubMed

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice.

Reishi & Liver: Risk Assessment

Metric	Value
Documented liver cases	dozens worldwide
NIH LiverTox rating	extremely rare
High-risk form	unextracted powder
Lower-risk form	standardized extract
Mechanism suspected	triterpenoid load
Source: YourHealthier · NIH LiverTox; case reports; extraction method data

Chart: Reishi & Liver: Risk Assessment. Data: Documented liver cases: dozens worldwide; NIH LiverTox rating: extremely rare; High-risk form: unextracted powder; Lower-risk form: standardized extract; Mechanism suspected: triterpenoid load. Source: NIH LiverTox; case reports; extraction method data.